|
|
Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin.
Yvon Calmus
,
Christophe Duvoux
,
Georges Pageaux
,
Philippe Wolf
,
Lionel Rostaing
et al.
Journal articles
istex
hal-00865405v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Direct-acting antiviral agent-based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT study
Sébastien Dharancy
,
Audrey Coilly
,
Claire Fougerou-Leurent
,
Christophe Duvoux
,
Nassim Kamar
et al.
Journal articles
hal-01640061v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study
Audrey Coilly
,
Claire Fougerou-Leurent
,
Victor De Ledinghen
,
Pauline Houssel-Debry
,
Christophe Duvoux
et al.
Journal articles
hal-01395132v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values results from the ANRS CO23 CUPILT cohort
Aurélie Barrail-Tran
,
Lauriane Goldwirt
,
Thibaut Gelé
,
Claire Laforest
,
Audrey Lavenu
et al.
Journal articles
hal-02280498v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program
Christophe Hézode
,
Victor De Ledinghen
,
Hélène Fontaine
,
Fabien Zoulim
,
Pascal Lebray
et al.
Journal articles
hal-01380169v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?
Audrey Coilly
,
Jérôme Dumortier
,
Danielle Botta-Fridlund
,
Marianne Latournerie
,
Vincent Leroy
et al.
Journal articles
hal-01326372v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Sofosbuvir and NS5A inhibitors without Ribavirin during 12 weeks are efficient to treat hepatitis C recurrence after liver transplantation only in genotype 1. Results from the CO23 ANRS CUPILT study.
Pauline Houssel-Debry
,
Audrey Coilly
,
Claire Fougerou-Leurent
,
Caroline Jezequel
,
Christophe Duvoux
et al.
Hepatology, 2017, 63 (1 SUPP), pp.465A--465A
Journal articles
hal-01412958v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation
Pauline Houssel-Debry
,
Audrey Coilly
,
Claire Fougerou-Leurent
,
Caroline Jezequel
,
Christophe Duvoux
et al.
Journal articles
hal-01807755v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years?
Lucy Meunier
,
Mohamed Belkacemi
,
George Philippe Pageaux
,
Sylvie Radenne
,
Anaïs Vallet-Pichard
et al.
Journal articles
hal-03980202v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|